Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin signs binding term sheet with Ascendis, ending patent disputes for royalties

Neutral Impact 3 of 5 legal/regulatory Written later

BioMarin entered a binding term sheet with Ascendis Pharma on August 30, 2026, to settle all pending proceedings over its patent rights covering the C-type natriuretic peptide TransCon CNP (navepegritide, Yuviwel). Ascendis will pay BioMarin royalties on Licensed Product sales, and the parties will dismiss all related litigation with prejudice, including the ITC Section 337 investigation. The filing gives no financial value for the settlement or the royalties beyond the rates, so the effect on BioMarin's results cannot be measured from this filing.

Key points

  • Royalty of 20% of annual net sales in the United States and 18% in the European Union, Brazil and South Korea, running until May 2030
  • BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to its patents for all current and potential indications, including achondroplasia and hypochondroplasia
  • Term sheet is binding as of August 30, 2026; parties must sign the full Agreement by September 24, 2026, or the term sheet terms continue to bind

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECAug 31, 2026, 6:01 AM ET
Accession number0001193125-26-375275

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 31, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.